Key result
Platelets mitigate early MASLD lipid accumulation and inflammation by preserving sinusoidal endothelial fenestration via nitric oxide.
Why the study?
Although studies have highlighted the impact of antiplatelet therapies on MASLD, how platelets are involved in liver metabolic dysregulation during disease initiation and early progression remains ill-defined.
Does platelet modulation affect liver sinusoidal endothelial cell fenestration and early disease progression in murine models of MASLD?
Does platelet modulation affect liver sinusoidal endothelial cell fenestration and early disease progression in murine models of MASLD?
Answers are grounded in this paper and cite their sources.
This preclinical study reveals a protective role for platelets in early MASLD via enhancement of hepatic endothelial fenestration, suggesting that the timing of antiplatelet therapy may be an important consideration in MASLD management.
BACKGROUND: Although studies have highlighted the impact of antiplatelet therapies on metabolic dysfunction-associated steatotic liver disease (MASLD), how platelets are involved in liver metabolic dysregulation, especially in the initiation of the disease and its early progression, still remains ill-defined. METHODS: We used nutritional preclinical murine models that exhibit steatosis and early metabolic dysfunction-associated steatohepatitis combined with genetic or pharmacological approaches to modulate platelet count and activation. RESULTS: Our study is the first to reveal a protective role for blood platelets in maintaining liver homeostasis during the early stages of MASLD. We demonstrate that platelets safeguard the liver microenvironment by mitigating 2 key pathological features of early MASLD, lipid accumulation, and inflammation. Platelets accumulate in liver sinusoidal microvessels under steatosis and metabolic dysfunction-associated steatohepatitis, and ameliorate these disease stages by promoting hepatic vascular permeability and enhancing the fenestration of liver sinusoidal microvessels. Critically, we identify that platelets directly regulate liver sinusoidal endothelial cell activation and fenestration, a vital component of liver microvascular function. Mechanistically, this protective effect is mediated through platelet releasate, which increases liver sinusoidal endothelial cell fenestration via an autocrine nitric oxide-dependent signaling pathway. CONCLUSIONS: This study uncovers a novel protective role of platelets in the early stages of MASLD by modulating the phenotype of liver sinusoidal endothelial cells and preserving microvascular integrity through their releasate. These findings challenge the prevailing view of platelets as solely detrimental in MASLD and raise important considerations for the timing of antiplatelet therapies in MASLD management.
No takes yet. Share an insight, caveat, or question.
Borret et al. (2026) studied Metabolic dysfunction-associated steatotic liver disease (MASLD). Genetic or pharmacological modulation of platelet count and activation was evaluated on Hepatic lipid accumulation, inflammation, and liver sinusoidal endothelial cell fenestration. Blood platelets mitigated hepatic lipid accumulation and inflammation in early MASLD by increasing liver sinusoidal endothelial cell fenestration via an autocrine nitric oxide pathway.
Synapse has enriched 10 related papers. Consider them for comparative context: